Avalanche Biotechnologies and Lonza have entered a manufacturing collaboration focused on process development and scale-up for adeno-associated viral (AAV) vectors for gene therapy. AAV vectors are promising gene delivery vehicles for the treatment of various diseases including inherited retinal disorders, age-related macular degeneration (AMD), hemophilia B, congestive heart failure, and Parkinson’s disease. Terms of the agreement were not disclosed.   The two companies will make the technology...